Actions
Atlanta
,
USA
4 - 7 November 2025
The Obesity Society (Obesity Week 2025)
Presentation schedule and materials
Tuesday, 04 November 2025
19:30
- 20:30
ET
POSTER
Real-World Physician and Patient Perspectives on Compliance and Adherence of Semaglutide for Obesity or Overweight
Yiqiao Zhang1; Zhenxiang Zhao1; Andrea Leith2; Sophie Barlow2; Bríain Ó Hartaigh1; Anthony Fabricatore1
MATERIALS AVAILABLE
Coming soon
19:30
- 20:30
ET
POSTER
Factors Related to Adherence and Compliance in Patients With Overweight or Obesity Receiving Semaglutide for Weight Management
Yiqiao Zhang1; Zhenxiang Zhao1; Andrea Leith2; Sophie Barlow2; Bríain Ó Hartaigh1
MATERIALS AVAILABLE
Coming soon
19:30
- 20:30
ET
POSTER
Efficacy of oral semaglutide 25 mg in people with overweight or obesity and poor physical function
Domenica Rubino1; Oscar Birkhan2; W. Timothy Garvey3; Ildiko Lingvay4; Naveen Rathor2; Chaithra Shaji5; Sean Wharton6,7,8,9
MATERIALS AVAILABLE
Coming soon
19:30
- 20:30
ET
POSTER
Semaglutide Effect on Physical Functioning in Adults with Obesity and Knee Osteoarthritis
Henning Bliddal1; Harold Bays2; Johan Jendle3; Kristoffer Jensen Kolnes4; Thomas Hoffmann Morville4; Chaithra Shaji5; Sean Wharton6,7,8,9
MATERIALS AVAILABLE
Coming soon
19:30
- 20:30
ET
POSTER
Association between body mass index and surgeries for knee and hip joint replacements
Arunima Hait1; Inger Smith2; Timothy Arnaut3
MATERIALS AVAILABLE
Coming soon
19:30
- 20:30
ET
POSTER
Changes in alcohol and tobacco spending among users and non-users of semaglutide for weight management
Timothy Arnaut1; Katya Kazantseva2; Kajsa Kvist1; Bríain Ó Hartaigh3
MATERIALS AVAILABLE
Coming soon
Wednesday, 05 November 2025
08:15
- 08:30
ET
ORAL PRESENTATION
Improvements in Glycemic Parameters and Cardiovascular Risk Factors with Oral Semaglutide 25 mg
Domenica Rubino1; Oscar Birkhan2; W. Timothy Garvey3; Naveen Rathor2; Chaithra Shaji4; Sean Wharton5,6,7,8; Ildiko Lingvay9
MATERIALS AVAILABLE
Coming soon
14:30
- 15:30
ET
POSTER
Semaglutide Reduces Body Weight Regardless of Menopause Status: STEP and OASIS 4 Post Hoc Analysis
Maria Daniela Hurtado Andrade1; Rebecca Dunsmoor-Su2; Emilia Huvinen3; Naveen Rathor4; Nanette Santoro5; Lauren Wilson6; Sushmita Yaganti6; Santiago Palacios7
MATERIALS AVAILABLE
Coming soon
14:30
- 15:30
ET
POSTER
CagriSema Reduces hsCRP in Adults With Overweight or Obesity: the REDEFINE 1 Trial
Pam R Taub1; Matthias Blüher2; Morten Böttcher3; Paul Brown4; Paolo Sbraccia5; Lærke Smedegaard4; Rasmus Sørrig4; John PH. Wilding6; Ildiko Lingvay7
MATERIALS AVAILABLE
Coming soon
15:30
- 15:45
ET
ORAL PRESENTATION
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: the REDEFINE 1 Trial
Subodh Verma1; Morten Böttcher2; Paul Brown3; Dror Dicker4; Domenica Rubino5; Paolo Sbraccia6; Arya M. Sharma7; Lærke Smedegaard3; Rasmus Sørrig3; W. Timothy Garvey8
MATERIALS AVAILABLE
Coming soon
15:45
- 16:00
ET
Oral-056
ORAL PRESENTATION
Effect of CagriSema 2.4mg/2.4mg on Body Composition, Muscle Strength & Physical Function
Eric Ravussin1; Cynthia Karenina Osorto Contreras2; Gema Frühbeck3; Christoffer Andersen Hagemann2; Alexander D. Miras4; John Morton5; Niels Zeuthen2; Carla M. Prado6
MATERIALS AVAILABLE
Coming soon
16:15
- 16:30
ET
ORAL PRESENTATION
Effect of Semaglutide 2.4 mg in Chinese Adults With Overweight or Obesity (BMI ≥24 or ≥28): STEP 12
Lixin Guo1; Xiaolei Bao2; Kristoffer Jensen Kolnes3; Christian Laugesen3; Yibing Lu4; Bifen Luo2; Guoyue Yuan5; Robert Kushner6
MATERIALS AVAILABLE
Coming soon
16:30
- 16:45
ET
ORAL PRESENTATION
STEP UP: Efficacy of Semaglutide in Obesity Treatment Targets and Cardiovascular Risk Thresholds
Carel W le Roux1; W. Timothy Garvey2; Kristoffer Jensen Kolnes3; Jøran Hjelmesæth4; Ildiko Lingvay5; Niklas Kahr Rasmussen3; Volker Schnecke3; Luca Busetto6
MATERIALS AVAILABLE
Coming soon
Thursday, 06 November 2025
14:30
- 15:30
ET
POSTER
CagriSema Reduces Predicted ASCVD Risk in Adults With Overweight or Obesity: the REDEFINE 1 Trial
Subodh Verma1; Morten Böttcher2; Paul Brown3; Dror Dicker4; Domenica Rubino5; Paolo Sbraccia6; Arya M. Sharma7; Lærke Smedegaard3; Rasmus Sørrig3; W. Timothy Garvey8
MATERIALS AVAILABLE
Coming soon
14:30
- 15:30
ET
POSTER
CagriSema and achievement of BMI and waist-to-height ratio treatment targets: REDEFINE 1
Luca Busetto1; Cynthia Karenina Osorto Contreras2; Mikkel Hovden Christensen2; Deborah Horn3; Carel W. le Roux4,5; Barbara McGowan6; Claire Prener Miller2; W. Timothy Garvey7
MATERIALS AVAILABLE
Coming soon
16:00
- 16:15
ET
ORAL PRESENTATION
REDEFINE 5: CagriSema in East Asian Adults With Overweight or Obesity, With or Without T2D
Yasushi Ishigaki1; Niels-Peter Becker2; Christoffer Andersen Hagemann2; Kuo-Chin Huang3; Arihiro Kiyosue4; Soo Lim5; Yukiko Onishi6; Ananda Kosuvaripalli2; Tomoko Takano7; Toshimasa Yamauchi8
MATERIALS AVAILABLE
Coming soon
Actions
Keywords